Virios Therapeutics news covers a development-stage biotechnology company focused on antiviral therapies for diseases associated with a virally triggered abnormal immune response, including fibromyalgia and Long-COVID. Company updates have centered on fixed-dose antiviral and celecoxib combinations, including IMC-1, a famciclovir-and-celecoxib candidate with FDA Fast Track designation, and IMC-2, a valacyclovir-and-celecoxib candidate studied in Long-COVID.
Recurring developments include clinical and regulatory updates, quarterly financial results, cash runway commentary, public equity offerings, shareholder voting matters, governance items and capital-structure disclosures tied to VIRI common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.